We previously analyzed the number of CTCs and the expression of PD-L1 on CTCs in 38 advanced NSCLC patients treated with nivolumab at the baseline and observed a significant difference between the rate of PD-L1-positive CTCs in the detected CTCs from patients and the response to nivolumab treatment [30]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.